Taylor A M, Metcalfe J A, Thick J, Mak Y F
CRC Institute for Cancer Studies, Medical School, University of Birmingham, UK.
Blood. 1996 Jan 15;87(2):423-38.
There is a large increase in lymphoid malignancy in A-T patients and a total absence of myeloid tumors. Penetrance of the tumor phenotype is about 10% to 15% by early adulthood. The increase in lymphoid malignancy includes both B- and T-cell tumors. However, young A-T patients do not show an increased susceptibility to cALL, and the UK data suggest that B-cell lymphoma occurs in older A-T children. T-cell tumors may occur at any age and may be T-ALL, T-cell lymphoma, or T-PLL; most strikingly, there may be a fourfold to fivefold increased frequency of T-cell tumors compared with that of B-cell tumors in these patients. If this is correct, it is possible that a significant proportion of all T-ALL/T-cell lymphoma in infants might be associated with undiagnosed A-T. The age range and sex predominance for T-ALL may be different for A-T and non-A-T patients and the age range for T-PLL may also be different in A-T and non-A-T patients. There is clearly some uncertainty concerning the ratio of T-cell to B-cell tumors in A-T, but this could be clarified by the publication of all tumors that occur in the disorder. In contrast, 8 of 9 tumors reported in NBS, which shows the same cellular features as A-T, were lymphomas and none was a leukemia. There are several indicators of genetic heterogeneity in A-T that suggest that not all patients are equally susceptible to all T-cell tumor types. Concordance for tumor type within individual families suggests that particular gene defects may be associated with particular tumor types. The logical extrapolation of this argument is that some patients may not have any increased risk for B-cell tumors at all or even to all T-cell types but only to a particular type of T-cell tumor. What is the cause of the increased predisposition to leukemia/lymphoma in A-T patients? There is no evidence that the immunodeficiency in A-T is related to this predisposition. One of the major findings in all A-T patients is the increase in V(D)J-mediated chromosome rearrangement observed in T lymphocytes. Particular chromosome translocations in T cells, involving a break in a TCR gene, are characteristically associated with either T-ALL or T-PLL in non-A-T patients. The majority of T-cell tumors in A-T are T-ALL and T-cell lymphoma, about which virtually nothing is known chromosomally, and the assumption is that the increased number of translocations leads to the increased level of these tumors. In older T patients, the expansion of specific translocation T-cell clones has been followed to the point to which they develop into T-PLL. All the evidence, therefore, suggests that the A-T mutation in the homozygous state allows a large increase in production of translocations formed at the time of V(D)J recombination, and this leads to the increased predisposition to leukemia. The general increased predisposition to T-cell tumors compared with B-cell tumors in A-T patients may be related to a preferential occurrence of translocations in T cells. Relatively little is known about translocations in circulating B lymphocytes in normal individuals, but A-T siblings have been shown to have clonal chromosome rearrangements of both B and T cells, simultaneously, although in these siblings the T-cell clones occupied all the T-cell compartment and the B-cell clones were small. An important inference from these facts is that the A-T defect preferentially affects immune system gene recombination in T cells rather than B cells. Recent evidence suggests that the V(D)J recombination machinery is not identical or is not regulated identically in T- and B-cell progenitors. This finding is consistent with the hypothesis that V(D)J rejoining in the majority, at least, of A-T patients may be preferentially deficient in T cells compared with B cells giving rise to the greatly increased number of translocations and T-cell tumors. Carbonari et al proposed that the recombination defect in A-T cells affected both Ig isotype switching and TCR rearrangeme
共济失调毛细血管扩张症(A-T)患者的淋巴恶性肿瘤大幅增加,而髓系肿瘤则完全不存在。到成年早期,肿瘤表型的外显率约为10%至15%。淋巴恶性肿瘤的增加包括B细胞和T细胞肿瘤。然而,年轻的A-T患者对儿童急性淋巴细胞白血病(cALL)的易感性并未增加,英国的数据表明B细胞淋巴瘤发生在年龄较大的A-T儿童中。T细胞肿瘤可在任何年龄发生,可能是T细胞急性淋巴细胞白血病(T-ALL)、T细胞淋巴瘤或T细胞原淋巴细胞白血病(T-PLL);最引人注目的是,与B细胞肿瘤相比,这些患者中T细胞肿瘤的发生频率可能增加了4至5倍。如果这是正确的,那么婴儿中所有T-ALL/T细胞淋巴瘤的很大一部分可能与未被诊断出的A-T有关。A-T患者和非A-T患者的T-ALL的年龄范围和性别优势可能不同,A-T患者和非A-T患者的T-PLL的年龄范围也可能不同。关于A-T中T细胞与B细胞肿瘤的比例显然存在一些不确定性,但这可以通过公布该疾病中发生的所有肿瘤来澄清。相比之下,共济失调伴眼皮肤毛细血管扩张症(NBS)报告的9个肿瘤中有8个是淋巴瘤,没有一个是白血病,NBS与A-T具有相同的细胞特征。A-T中存在几种遗传异质性指标,这表明并非所有患者对所有T细胞肿瘤类型的易感性都相同。个体家庭中肿瘤类型的一致性表明特定的基因缺陷可能与特定的肿瘤类型相关。这个论点的合理推断是,一些患者可能根本没有B细胞肿瘤的风险增加,甚至对所有T细胞类型都没有增加风险,而只是对特定类型的T细胞肿瘤有增加风险。A-T患者白血病/淋巴瘤易感性增加的原因是什么?没有证据表明A-T中的免疫缺陷与这种易感性有关。所有A-T患者的主要发现之一是在T淋巴细胞中观察到V(D)J介导的染色体重排增加。在非A-T患者中,T细胞中涉及TCR基因断裂的特定染色体重排通常与T-ALL或T-PLL相关。A-T中的大多数T细胞肿瘤是T-ALL和T细胞淋巴瘤,关于它们的染色体情况几乎一无所知,推测是重排数量的增加导致了这些肿瘤水平的升高。在年龄较大的A-T患者中,特定重排T细胞克隆的扩增一直追踪到它们发展为T-PLL的阶段。因此,所有证据表明,纯合状态的A-T突变会使V(D)J重组时形成的重排产生大幅增加,这导致白血病易感性增加。与B细胞肿瘤相比,A-T患者中T细胞肿瘤的总体易感性增加可能与T细胞中重排的优先发生有关。关于正常个体循环B淋巴细胞中的重排了解相对较少,但已表明A-T患者的兄弟姐妹同时存在B细胞和T细胞的克隆染色体重排,尽管在这些兄弟姐妹中,T细胞克隆占据了所有T细胞区室,而B细胞克隆较小。从这些事实得出的一个重要推论是,A-T缺陷优先影响T细胞而非B细胞中的免疫系统基因重组。最近的证据表明,V(D)J重组机制在T细胞和B细胞祖细胞中并不相同或调控方式不同。这一发现与以下假设一致,即至少在大多数A-T患者中,与B细胞相比,T细胞中的V(D)J重接可能优先存在缺陷,从而导致重排数量和T细胞肿瘤大幅增加。卡尔博纳里等人提出,A-T细胞中的重组缺陷影响了Ig同种型转换和TCR重排。